The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Esteban Ribera

Department of Infectious Diseases

Hospital Universitari Vall d'Hebron




Name/email consistency: high



  • Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 2005 - 2008
  • Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Paseo Vall Hebron 119-129, 08035 Barcelona, Spain. 2004 - 2006


  1. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). Ribera, E., Paradiñeiro, J.C., Curran, A., Sauleda, S., García-Arumí, E., Castella, E., Puiggròs, C., Crespo, M., Feijoo, M., Diaz, M., Del Saz, S.V., Planas, M., Sureda, D., Falcó, V., Ocaña, I., Pahissa, A. HIV. Clin. Trials (2008) [Pubmed]
  2. Double-boosted protease inhibitor antiretroviral regimens: what role? Ribera, E., Curran, A. Drugs (2008) [Pubmed]
  3. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Ribera, E., Azuaje, C., Lopez, R.M., Domingo, P., Curran, A., Feijoo, M., Pou, L., Sánchez, P., Sambeat, M.A., Colomer, J., Lopez-Colomes, J.L., Crespo, M., Falcó, V., Ocaña, I., Pahissa, A. J. Antimicrob. Chemother. (2007) [Pubmed]
  4. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Ribera, E., Azuaje, C., Lopez, R.M., Diaz, M., Feijoo, M., Pou, L., Crespo, M., Curran, A., Ocaña, I., Pahissa, A. AIDS (2006) [Pubmed]
  5. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera, E., Rodríguez-Pardo, D., Rubio, M., Soler, A., Pedrol, E., Blanco, J.L., González, A., Crespo, M., Falcó, V., Ocaña, I., Deig, E., Miró, J.M., Pahissa, A. Antivir. Ther. (Lond.) (2005) [Pubmed]
  6. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). Ribera, E., Azuaje, C., Lopez, R.M., Domingo, P., Soriano, A., Pou, L., Sánchez, P., Mallolas, J., Sambea, M.A., Falco, V., Ocaña, I., Lopez-Colomes, J.L., Gatell, J.M., Pahissa, A. J. Acquir. Immune Defic. Syndr. (2005) [Pubmed]
  7. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Ribera, E., Lopez, R.M., Diaz, M., Pou, L., Ruiz, L., Falcó, V., Crespo, M., Azuaje, C., Ruiz, I., Ocaña, I., Clotet, B., Pahissa, A. Antimicrob. Agents Chemother. (2004) [Pubmed]
WikiGenes - Universities